Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2001
07/05/2001US20010006974 Combination therapy for lymphoproliferative diseases
07/05/2001US20010006973 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
07/05/2001US20010006972 Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
07/05/2001US20010006971 Administering an antiallergen of loratadine or metabolite of loratadine, desloratadine; migraines, stroke, orthostatic hypotension, gastrointestinal stasis, nausea, dizziness and jet lag; also psychological disorders; 5-HT7 receptors
07/05/2001US20010006970 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
07/05/2001US20010006968 Use of ophthalmic agent
07/05/2001US20010006967 Administering an analgesic amount of tramadol and an amount of an excitatory opioid receptor antagonist, e.g naltrexone, nalone, to lessen the antianalgesia, hyperalgesia, hyper-excitability, physical dependence and or tolerance
07/05/2001US20010006966 Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action
07/05/2001US20010006965 E.g., alpha-(1-((4-methylsulfonylbenzylidene)-2-methyl-5-fluoro-inden-3-yl)acetic acid or the methyl ester
07/05/2001US20010006963 Containing estrogenic and gestagenic components; drug delivery; time-release agents; reliable contraceptive effect; osteoporosis pevention; tolerance and cycle control
07/05/2001US20010006962 Behavior of biologically active compounds favorably modified by replacing a functional group with an unsaturated fatty derivative, e.g. elaidic acid; bioavailability; membrane passage; organ targeting; drugs; agriculture
07/05/2001US20010006960 Human or veterinary medicine, especially horses, involving lameness with an osseous, articular or osteoarticular component and not involved with arthritus or fractures; no increase in bone density; e.g., tiludronic acid and salts
07/05/2001US20010006959 Displaying a beta-lactamase inhibitor protein on a virus, contacting the virus with a beta-lactamase binding protein target, selecting for the virus that has a higher affinity for the target and testing the beta-lactamase inhibitor protein
07/05/2001US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity
07/05/2001US20010006954 Synthetic DNA comprising a radiation responsive enhancer-promoter operatively linked to a polypeptide encoding region linked to a transcription terminating region; regulating gene expression and inhibiting tumor growth
07/05/2001US20010006946 Improved gene transfer efficiency by coadministering with a cholic acid or deoxycholic acid amide derivative of given formula
07/05/2001US20010006944 Treating noninvasive fungus-induced rhinosinusitis by mucoadministering an antifungal agent; culturing noninvasive fungus from a mammalian mucus sample for antigen/antibody production; apparatus for collecting nasal mucus
07/05/2001US20010006941 Composition for inhibiting increase of blood sugar level or lowering blood sugar level
07/05/2001US20010006817 Cell delivery compositions
07/05/2001US20010006816 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
07/05/2001US20010006815 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
07/05/2001US20010006814 Chemical modification
07/05/2001US20010006784 Apolipoprotein e polymorphism and treatment of alzheimer's disease
07/05/2001US20010006682 Administering parenterally to the patient having suppressed immune system, an effective treatment amount of Product R, a peptide-nucleic acid preperation, alone or in combination with one or more immuno-modulators
07/05/2001US20010006681 Chemokine inhibition of immunodeficiency virus
07/05/2001US20010006674 Mixture for use as wound dressing
07/05/2001US20010006673 Feeding the animal(dog or cat) a diet containing an effective amount of lutein for a time sufficient for the lutein to be absorbed into the bloodstream of the animal
07/05/2001US20010006671 Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
07/05/2001US20010006669 An antiseptic sealed package of solid dry admixed polyvinylpyrrolidone-cinnamic alcohol emulsion, the external surface of emulsion carries a coating of cinnamic alcohol liquefied from the solid emulsion and then dried thereupon
07/05/2001US20010006662 A lipid regulating agent selected from a fibrate or statin dispersed or dissolved in a hydrophilic, amorphous polymer in which antilipidimic agent present as metastable, amorphous phase
07/05/2001US20010006655 Process for preparing solid formulations of lipidregulating agents with enhanced dissolution and absorption
07/05/2001US20010006649 Stable oral pharmaceutical dosage forms
07/05/2001US20010006644 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
07/05/2001US20010006642 Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides
07/05/2001US20010006640 Compounds and methods to inhibit or augment an inflammatory response
07/05/2001US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response
07/05/2001US20010006625 Comprising one or more glucocorticoids, physiologicall tolerable solvent(s), and water insoluble film-forming agents
07/05/2001US20010006620 Such a hirudin or oral thrombin inhibitor, by determining from the ratio of the dose given to the measured ecarin clotting time using a computer statistical analysis program
07/05/2001US20010006619 Compounds for cancer imaging and therapy
07/05/2001US20010006616 Polymeric delivery of radionuclides and radiopharmaceuticals
07/05/2001US20010005930 Method of making a hollow-tube precursor brachytherapy device
07/05/2001DE19963319A1 Orale pharmazeutische Zubereitung An oral pharmaceutical preparation
07/05/2001DE19963235A1 Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel Substituted piperazine derivatives, their preparation and their use as medicaments
07/05/2001DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases
07/05/2001DE19962924A1 Substituierte Oxazolidinone und ihre Verwendung Substituted oxazolidinones and their use
07/05/2001DE19962901A1 Azolylalkalylazol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel Azolylalkalylazol-derivatives, processes for their preparation and their use as pesticides
07/05/2001DE19960924A1 Amphiphile Polyamine, deren Anwendungen und Verfahren zu ihrer Synthese Amphiphilic polyamines, their applications and methods for their synthesis
07/05/2001DE19960443A1 Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen A method for finding nucleotide synthesis inhibitors with fewer side effects
07/05/2001CA2699568A1 Azaindoles
07/05/2001CA2396713A1 Novel bisamidate phosphonate prodrugs
07/05/2001CA2396693A1 Cytokine, especially tnf-alpha, inhibitors
07/05/2001CA2396579A1 Tricyclic protein kinase inhibitors
07/05/2001CA2396533A1 Treatment of ischemic brain injuries with brain targetted antioxidant compounds
07/05/2001CA2396516A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
07/05/2001CA2396502A1 Substituted pyrrole mannich bases
07/05/2001CA2396380A1 Improved pharmaceutical compositions for poorly soluble drugs
07/05/2001CA2395996A1 Neuroprotective drug
07/05/2001CA2395993A1 Antidiabetic preparation for oral administration
07/05/2001CA2395716A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
07/05/2001CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors
07/05/2001CA2395575A1 Uses of transport proteins for controlling cell cycle
07/05/2001CA2395561A1 Benzophenone glycopyranosides, preparation and therapeutic use
07/05/2001CA2395557A1 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use
07/05/2001CA2395548A1 Imidazo 1,3,5 triazinones and the use thereof
07/05/2001CA2395544A1 Method of achieving persistent transgene expression
07/05/2001CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors
07/05/2001CA2395535A1 Method for the production of vitamin a
07/05/2001CA2395524A1 Chemotherapeutant screening method
07/05/2001CA2395430A1 Treatment of drug-resistant human immunodeficiency virus infection
07/05/2001CA2395418A1 Isoxazolo pyrimidinones and the use thereof
07/05/2001CA2395410A1 Triazolotriazinones and the use thereof
07/05/2001CA2395345A1 Use of azoles for preventing skin cancer
07/05/2001CA2395335A1 Genes identified as required for proliferation of e. coli
07/05/2001CA2395320A1 Therapeutic uses of lna-modified oligonucleotides
07/05/2001CA2395305A1 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes
07/05/2001CA2395284A1 Inhibition of gsk-3.beta.
07/05/2001CA2395276A1 Identification of novel splice variants of the human catalytic subunit c.beta. of camp-dependent protein kinase and the use thereof
07/05/2001CA2395275A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof
07/05/2001CA2395273A1 A novel isoform of human camp-dependent protein kinase, c.alpha.-s, localizes to sperm midpiece and the use thereof
07/05/2001CA2395259A1 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect
07/05/2001CA2395249A1 Substituted piperazine derivatives, the preparation thereof and their use as medicaments
07/05/2001CA2395236A1 Basolateral sorting signal and inhibitors thereof
07/05/2001CA2395205A1 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity
07/05/2001CA2395179A1 Nitrile derivatives as cathepsin k inhibitors
07/05/2001CA2395173A1 Pyrrolidines which inhibit camp-specific pde
07/05/2001CA2395003A1 Dioxygenases catalyzing the asymetric cleavage of beta-carotene
07/05/2001CA2394944A1 Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein
07/05/2001CA2394888A1 Compound and method for the treatment of pain
07/05/2001CA2394880A1 Activation and inhibition of the immune system
07/05/2001CA2394747A1 Use of trimebutine for treating pain
07/05/2001CA2394745A1 Combination of trimebutine with an opioid analgesic
07/05/2001CA2394727A1 Pyrimidine and triazine kinase inhibitors
07/05/2001CA2394644A1 Substituted piperazine derivatives,the preparation thereof and their useas medicaments
07/05/2001CA2394561A1 Method and composition for the treatment of pain
07/05/2001CA2394393A1 Remedies for external use for allergic skin diseases
07/05/2001CA2394098A1 Substituted 1 and 2 naphthol mannich bases
07/05/2001CA2394097A1 New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
07/05/2001CA2393916A1 Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
07/05/2001CA2393583A1 Compounds active at the glucocorticoid receptor
07/05/2001CA2392866A1 Substituted indole mannich bases